Project Grant R01HL178419
Award Date
8/1/25
Completion Date
5/31/30
Dollars Obligated
$507K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $735,838 to the University of Arizona to conduct research on the role of hexokinase 1 (HK1) mitochondrial binding in cardiac endothelial cell function and the development of heart failure with preserved ejection fraction (HFpEF). The research aims to determine if HK1 mitochondrial dislocation leads to increased protein O-GlcNAcylation,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $385,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the RU School of Osteopathic Medicine in Pennsylvania. The 5-year grant, which commenced on January 20, 2025, aims to investigate the role of mitochondrial magnesium in regulating mitochondrial calcium uptake and its impact on ischemic reperfusion injury and heart failure. The key objectives are to: 1) define the mechanism by which oxidative stress...
The federal Project Grant award F31HL174083, totaling $145,642.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research to investigate the molecular mechanisms that regulate the mitochondrial calcium uniporter, a key regulator of mitochondrial function. The goal is to increase understanding of mitochondrial calcium signaling and inform the development of therapies for diseases...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $125,568 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Stanford University. The grant supports research to explore the molecular mechanisms governing the import and regulation of NAD+ within the mitochondrial matrix. This work aims to elucidate how mitochondria maintain adequate NAD+ levels and how this process may become dysregulated in heart failure, a major global health issue. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $173,352 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Vanderbilt University Medical Center (VUMC) to conduct research on molecular characterization of frailty and functional limitations in heart failure with preserved ejection fraction (HFpEF). The key products and services to be delivered under this 5-year award, which began on Jul 15, 2025, include: Measuring associations between the human proteome and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $259,464 to The Leland Stanford Junior University to conduct research on "Mitochondrial Therapy in Conjunction with Guideline Directed Medical Therapy in Cardiomyopathy". The primary objectives are to: 1) Determine the mechanism of the protective effects of mitochondria-rich extracellular vesicles (M-EVs) in combination with guideline-directed...